Novus Pharma Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Boston MA United States (2004)

Organization Overview

First Clinical Trial
2009
NCT00959959
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Anelixis Therapeutics, Inc. | Anelixis Therapeutics, LLC | Novus Therapeutics, Inc | Tokai Pharmaceuticals | Tokai Pharmaceuticals, Inc.

Active Ingredients

Drugs in Phase 3 Trials (2)

enzalutamide (xtandi) (1 trial)

galeterone (4 trials)

Drugs in Phase 2 Trials (5)

Key: Novus Pharma (3) Acquired (2)

amoxicillin (1 trial)

at-1501 (2 trials)

ciprofloxacin (cipro) (3 trials)

clavulanate (Augmentin) (1 trial)

urea (1 trial)

Drugs in Phase 1 Trials (1)

dipalmitoylphosphatidylcholine (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Amyotrophic Lateral Sclerosis (Phase 2)

Motor Neuron Disease (Phase 2)

Otitis (Phase 2)

Otitis Media (Phase 2)

Prostatic Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 13
  • # of Trial APIs: 8